‘Miracle': Kitten survives after one-hour washing machine horror
A Burmese kitten has miraculously escaped with his life after becoming trapped in a front loader washing machine at a Gold Coast home.
Nine-month-old Pablo was reportedly taking a nap inside the washing machine when his owner turned it on, unknowingly trapping him inside.
After the soapy 55-minute cycle, which had no clothes inside, Pablo was discovered in a critical condition and rushed to the emergency vet, SASH (the Small Animal Specialist Hospital.
SASH worker Ella Yarsley told 7NEWS that Pablo had suffered a 'brain injury, lung injury and lost several toes' in the accident.
'He was probably in the most dire condition I've seen in a case in a long time,' she said.
'Not many have seen cats go through a whole cycle and survive … it was pretty close to a miracle.'
Thankfully, Pablo is said to be 'almost back to full health'.
In an almost identical incident, a Burmese cat on Queensland's Sunshine Coast became trapped in a hot cycle in July 2020.
Oscar, 2, had been seeking a nap inside the warm machine before he was put through a horror 12-minute cycle with detergent.
Oscar's owner Amanda Meredith, who lives in Mudjimba, told ABC at the time she heard a strange meowing sound after her husband, Angelo, put the bed sheets in the front loader washing machine.
Assuming the sound was coming from the cupboard, Ms Meredith went to hang out another load of washing – though when she came back inside and heard continued meowing, she realised Oscar was in the machine.
'The poor little cat had his hands on the glass as he was doing the rotations and he was looking at me,' she said.
'It was tragic.'
The Sunshine Coast vet who treated the pet, Dan Capps, told the ABC he was 'a very lucky but strong little fellow'.
'This is not the first time this has happened. During the cooler weather it is the perfect place for feline friends to try and hide for a warm nap,' Dr Capps said.
Cat owners are urged to always check the inside of their machines before turning them on.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
an hour ago
- ABC News
Is private health insurance worth it? What to weigh up at tax time
As Australians prepare to do their tax returns and take stock of their financial affairs, those with and without private health insurance may be considering whether their cover is worthwhile. For many, it's not just a question about accessing the private health system — it can also be a maths equation that takes into account the tax penalties for not having coverage, if you earn above certain thresholds. For about 15 million Australians, private health insurance premiums jumped in April, after the federal government approved the biggest annual average premium hike in seven years. So, is health insurance a good deal for you? Here's what to consider when weighing it up. Australia's private health system is meant to complement Medicare by taking pressure off the public system. People who can afford it are incentivised to be treated privately, with shorter wait times for elective surgeries and the ability to choose their doctor. Successive governments have implemented policies designed to push people into the private system — like the Medicare Levy Surcharge (MLS). But the system is under strain as Australia's population ages, placing more pressure on public hospitals and increasing reliance on private health insurance. A report by EY for the federal government in 2023 found that for those aged over 75, average hospital claims were over $7,000 per person, while for 40–45-year-olds, the average hospital claim was about $850 per person. By 2064–65, nearly one-quarter of the population is projected to be aged 65 and over. "There are a lot of benefits and a lot of strengths of the private system," said Stephen Duckett, an honorary professor at the University of Melbourne and former secretary of the federal health department. To ensure they remain profitable, insurers have stripped back coverage, increased excess payments and hiked prices, leaving many Australians wondering if taking out cover is necessary. The answer depends on your income, age and health needs. Professor Duckett says for young, healthy Australians, private health insurance often provides little value. Some policies, he says, offer minimal benefits but are strategically priced just below the MLS threshold, enticing people to buy coverage that does little beyond avoiding a tax penalty — essentially, "junk insurance". The MLS is a tax that's been around since 1997 and is designed to encourage higher-income earners to take out private hospital cover. The tax ranges from 1 per cent to 1.5 per cent of income and kicks in once individuals earn above $97,000 or couples/families earn above $194,001. Professor Duckett said the MLS was "a strange concept [for] a private market". "Remember, the purpose of this is to force people into private health insurance who will not use the product at all, so that the risk pool is improved." Individuals can work out how much their MLS would be using the ATO's calculator. Whether your spouse and any dependent children have private hospital cover also affects your liability for the MLS. The surcharge is calculated when you process your tax return each year, rather than covered in your employer tax withholding, so may affect the amount of any tax refund or add to a tax bill. It's also based on the number of days you hold cover for, so if you don't have coverage for the full financial year, you may still end up paying tax. Greg Jericho, chief economist at The Australia Institute, said the private healthcare system was struggling "because it is not attractive to those who are least likely to need it, and [those people] are also the most likely to be profitable". In his opinion, private health insurance was not a good option for young Australians. "Possibly if they are in competitive sports and at higher risk of needing knee or shoulder surgery. But otherwise, there is no real need." He also said junk insurance policies had become more common. "In 2000, around 3 to 4 per cent of private health insurance policies had exclusions — now it is around 65 per cent. "Similarly, we have gone from around half of all policies having excess payments to now around 85 per cent. "So there are many more policies that don't cover much and which require co-payments should they be used." Introduced by the Howard government, Lifetime Health Cover (LHC) loading penalises those who don't take out private hospital cover by age 31. The penalty is an extra 2 per cent for every year someone does not have cover after age 31. It's capped at 70 per cent and removed after 10 years of continuous cover. Before this policy, only 30 per cent of people in their 30s had private health insurance. A campaign titled Run For Cover boosted this figure to 50 per cent, but uptake has since dropped back down, according to Mr Jericho. Mark Blades, an insurance analyst from Choice, warns that LHC loading often catches people off guard in their 40s. For example, a 41-year-old who first takes out private cover would be hit with a 20 per cent LHC loading on their premium. But he said in most cases, it works out better for people to just pay the loading when they need health insurance, rather than take out a basic policy to avoid it later in life. "Basic cover is essentially overpriced for what you're getting because you're getting very, very little," he said. Mr Jericho said many people did "not see actual value in private health insurance and are merely taking it out to avoid penalties". Once someone is over 31 years old and earns above $97,000 a year, a double whammy comes into play — the MLS if you don't have hospital cover, and the lifetime loading. Mr Blades said those earning above the threshold could take out a cheap cover to save a couple of hundred dollars, but he warned it would likely be "a product you can't really use". The government contributes about $7.5 billion annually to subsidise private health insurance through a rebate program. The rebate is means-tested and ranges from about 8 per cent to 32 per cent, depending on income and age. Individuals earning more than $151,001 and couples earning more than $302,001 are not eligible. However, it has been progressively reduced in recent years due to rising medical costs and Australia's aging population. The rebate is indexed and was dropped last year by a few percentage points. And it dropped again this year from 24.6 per cent to 24.3 per cent. While big health insurers tend to make it difficult for people to drop their policy and pick up a new one (due to waiting periods and losing unused benefits, for example) — especially for top-tier cover — it's worth checking what you're covered for and shopping around. There is a range of websites comparing the market, including from the government, that help consumers look up the details of exactly what their policy covers — called a Private Health Insurance Statement — and compare policies across all health insurers in Australia. Factors worth weighing up include waiting periods and exclusions. Also, some policies require you to take out extras as well as hospital cover. If you are considering a cheap hospital policy to avoid tax penalties, Choice's Mark Blades says you need to consider extra costs that could come into play if you do need to make a claim. "If you did use it, you would be out of pocket from paying the excess, which is usually about $750 for basic cover, and pay gap fees. Disclaimer: The information in this article is general in nature. If you need personalised advice, please see a professional.
News.com.au
an hour ago
- News.com.au
Update as alleged anti-Semitic nurses Ahmad Rashad Nadir, and Sarah Abu Lebdeh given NDIS bans
Two nurses charged with threatening to kill Israeli patients in a viral video have been banned from working with NDIS patients. Ahmad Rashad Nadir, and fellow nurse Sarah Abu Lebdeh, both aged 27, made international headlines in February after a video of the pair allegedly bragging about killing Israeli patients at Bankstown Hospital, in Sydney's west, went viral. The pair, who have both been stood down from their jobs by NSW Health, have also been hit with a two-year ban from working with NDIS participants. The order came into effect in May, a listing by the NDIS Quality and Safeguards Commission read. It prevents the nurses from working with any NDIS participants or engaging in any work for or on behalf of any NDIS provider, in any Australian state or territory. Ms Abu Lebdeh is charged with threatening violence to a group, using a carriage service to threaten to kill and using a carriage service to menace, harass or offend. Mr Nadir has been charged with using a carriage service to menace, harass or offend and possessing a prohibited drug. The pair remain on bail, and have not yet entered any pleas. However, Mr Nadir's lawyer Zemarai Khatiz told reporters outside the Downing Centre Local Court in March that he would 'intend to argue for the video to be excluded from court'. Mr Khatiz alleges the video was captured 'without the consent and knowledge' of his client. 'We will be challenging the admissibility of the video recording because it was a private conversation which was recorded by the person overseas without my client's consent and without his knowledge,' Mr Khatiz told NewsWire. 'That video recording was made secretly overseas and was unlawfully obtained.' Mr Khatiz also confirmed his client intends to plead not guilty. In the two-and-a-half minute video, recorded by Israeli influencer Max Veifer, the nurses allegedly threaten to kill Israelis who came to the hospital. Mr Veifer often uses Chatruletka and Omegle, online platforms that pair users in random video chats, to expose instances of anti-Semitism and also to learn English. 'Ahh,' Mr Nadir says in the clip. 'I'm gonna be really honest with you, you've actually got really, really beautiful eyes. 'But I'm so upset that you're Israeli … eventually you're gonna get killed and you're gonna go to Jahannam (hell). But those pretty eyes, they should stay in this world for longer.' The exchange quickly gets heated as Mr Veifer explains he served in the IDF (Israeli Defence Force). A woman's voice can then be heard off camera saying: 'you killed innocent people'. The woman's voice continues: 'So you kill innocent people to protect your country? What kind of soul do you have? You have no soul.' Mr Veifer then asked the pair: 'How are you doctors?' Abu Lebdeh then allegedly told Mr Veifer she wanted him to 'remember my face so you can understand that you will die the most disgusting death'. Mr Veifer then begins to ask 'Let's say an Israeli, God forbid …' 'I won't treat them, I'll kill them,' Ms Abu Lebdeh says. 'Not God forbid, I hope to God.' 'You'll kill them?' Mr Veifer is heard asking. Mr Nadir then said: 'OK you have no idea how many Israeli haram dogs came to this hospital and (makes throat slitting motion) I send them to Jahannam.' 'For real? If just Jewish people comes (sic) there …' Mr Veifer begins before the chat ends. Following the identification of Mr Nadir in February, Strike Force Pearl raided his home and seized a number of items. The pair will return to court at the end of the month.
Daily Telegraph
an hour ago
- Daily Telegraph
LTR Pharma completes ED study milestone
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. LTR Pharma & co-development partner Aptar Pharma complete extractables study on SPONTAN All identified compounds below ICH safety thresholds for nasal spray-mist erectile dysfunction treatment Leachables study initiated to support FDA regulatory submission under real-world storage conditions Special Report: LTR Pharma has completed a key extractables study for its SPONTAN intranasal spray for erectile dysfunction and kicked off a leachables study as part of a regulatory development program. LTR Pharma (ASX:LTP) said the extractables study, conducted under the supervision of co-development partner Aptar Pharma, evaluated the bottle and pump components of SPONTAN's container closure system. The study confirmed that all detected compounds were below ICH safety thresholds – the internationally recognised standards adopted by the US Food and Drug Administration (FDA) and regulatory authorities worldwide for pharmaceutical impurities. LTR Pharma said the identified compounds would be monitored in the ongoing leachables study. FDA requires extractables and leachables (E&L) studies for all pharmaceutical products to ensure packaging materials do not compromise product safety or efficacy. For nasal spray products, these studies must meet specific regulatory thresholds due to direct tissue exposure. Leachables study now underway The leachables study has started under Aptar Pharma's management, evaluating the potential migration of the compounds from packaging into SPONTAN under real-world storage conditions. LTR Pharma said SPONTAN used industry-standard bottle and pump components as used in multiple FDA-approved nasal spray products. The study will run for at least 24 months to support shelf-life requirements. Consistent with FDA practice for nasal sprays, the company can submit its application once sufficient robust data is available, with study completion continuing post-approval as standard. E&L studies form part of LTR Pharma's comprehensive regulatory strategy following its FDA pre-IND meeting, where the FDA confirmed the proposed development pathway. The company said E&L data were required for the chemistry, manufacturing and controls (CMC) section of its planned new drug application (NDA). With extractables results meeting regulatory requirements, the company progresses to the leachables phase for comprehensive regulatory submission data. Watch: LTR's new appointment Progress on SPONTAN and new US-targeted ROXUS LTR Pharma continues to progress SPONTAN through established regulatory pathways while building commercial foundations through its Australian early access programs. It is also progressing its new ED nasal spray called ROXUS, which offers a fast-track pathway to serve patients through the US personalised healthcare sector. As with SPONTAN, ROXUS is based on the common active ingredient vardenafil. It will be delivered via the 503(a)-compounding pharmacy pathway, which exempts drugs from the usual approval, labelling and manufacturing requirements. "The completion of our extractables study and commencement of the leachables phase keep our regulatory program on schedule,' LTR Pharma executive chairman Lee Rodne said. 'Working with Aptar Pharma provides us with their established expertise in nasal spray device development and FDA submissions. 'These studies are necessary steps in our development pathway, and we look forward to progressing through each regulatory milestone." This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as LTR Pharma completes study milestone for SPONTAN ED treatment
